ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0139

When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: PP02

When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens

(PP01-PP08) Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: PP01

When You Become the Story: A Journalist’s Approach to Managing Complex Care

(PP01-PP08) Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0539

Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0391

Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0436

Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0575

Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0010

XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease

(0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I

10:30AM-12:30PM: Abstract Number: 0113

ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice

(0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0628

Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:45AM-11:00AM: Abstract Number: 0776

Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial

Plenary I (0772–0776)

1:00PM-1:15PM: Abstract Number: 0801

Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study

Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

1:00PM-1:15PM: Abstract Number: 0807

Deciphering Synovitis in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

1:00PM-1:15PM: Abstract Number: 0777

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

1:00PM-1:15PM: Abstract Number: 0795

Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].